^
Association details:
| Biomarker: | FGFR2-CCDC6 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice
Excerpt:
The tumor tissues were harvested and transplanted in nude mice to establish mouse models bearing patient-derived xenograft (PDX) of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein....Compared with those in the control group, the mice in ponatinib group showed a significantly reduced tumor volume (P < 0.0001) and suppressed tumor cell proliferation with significantly increased cell apoptosis….Ponatinib can regulate FGFR signaling to inhibit the proliferation and induce apoptosis of tumor cells in mice bearing patient-derived cholangiocarcinoma xenograft with FGFR2 fusion.
DOI:
10.12122/j.issn.1673-4254.2020.10.10
Source:
Title:
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein
Excerpt:
...we report a novel cholangiocarcinoma PDX model expressing an FGFR2-CCDC6 fusion protein and demonstrate preclinical antitumor activity of the nonspecific multikinase inhibitors ponatinib and dovitinib and the FGFR-specific inhibitor BGJ389 against this tumor.
DOI:
https://dx.doi.org/10.1016%2Fj.canlet.2016.05.017
